GLP-1 Medicaid Coverage by State (2026): All 50 States

Thirteen state Medicaid programs cover GLP-1 medications for obesity treatment. Thirty-eight do not. That is the whole answer, and it is a smaller number than it was six months ago: KFF counted sixteen states in October 2025 and thirteen as of January 2026.

One thing to clear up first, because it is the most common confusion on this subject. The price of a GLP-1 does not vary by state. List prices are national, and so are the manufacturer self-pay programmes. What varies by state is coverage — specifically whether your state's Medicaid programme will pay for one when the reason is obesity rather than diabetes. That single distinction decides more than any regional price difference could.

Which states cover GLP-1s for obesity?

These thirteen state Medicaid programmes covered GLP-1s for obesity treatment under fee-for-service as of January 2026:

• Delaware
• Kansas
• Massachusetts
• Michigan
• Minnesota
• Mississippi
• Missouri
• North Carolina
• Rhode Island
• Tennessee
• Utah
• Virginia
• Wisconsin

Every other state is in the second group. That includes the four largest — California, Texas, Florida and New York — which between them hold roughly a third of the US population. If you are looking for a pattern in the thirteen, there is not an obvious one: they are not the wealthiest states, not concentrated in one region, and not aligned to one party.

Which states dropped coverage, and why?

This is the part a static table cannot tell you, and it is the more useful half of the picture.

KFF's 2025 Medicaid budget survey found sixteen states covering GLP-1s for obesity as of October 2025. By January 2026 the count was thirteen. Four states eliminated coverage in between:

• California
• New Hampshire
• Pennsylvania
• South Carolina

KFF attributes this to state budget pressure and the cost of covering these drugs at the volumes now being prescribed. That is a plausible reading and the utilisation figures below make it easy to see why.

North Carolina is the instructive case. It eliminated GLP-1 coverage from October 2025 during a budget stalemate in the legislature, then reinstated it in December 2025. So it appears in the thirteen — but its inclusion was a live political question two months earlier.

The direction of travel matters more than the snapshot. Coverage is contracting, not expanding. Any page that gives you a list without a date is telling you what was true at a moment it does not disclose.

Why Medicaid coverage varies at all

Federal Medicaid rules let states exclude drugs used for weight loss. That exclusion is optional, which is precisely why the map looks like this: each state decides for itself, and can revisit the decision in any budget cycle.

Two consequences follow that are easy to miss:

• Diabetes is treated differently. The exclusion is about weight-loss use. A GLP-1 prescribed for type 2 diabetes sits in an entirely different category, and coverage for it is far more widely available. This is why the same molecule can be covered or refused depending on which brand and which diagnosis is on the prescription — the mechanics of that are in the FDA-approved GLP-1 medications list.
• Coverage is not the same as access. Most states that cover these drugs attach prior authorisation, BMI thresholds, documented previous attempts at weight management, or step therapy. "Covered" can still mean a queue and a form.

Fee-for-service versus managed care

The figures above describe fee-for-service Medicaid. Most Medicaid enrollees are in managed care plans, and those plans can set their own drug policies within state rules.

The practical implication is uncomfortable but worth stating plainly: your state appearing on the list of thirteen does not guarantee your plan covers it, and a state being absent does not always mean every plan refuses. The list tells you what the state does directly. Your plan's own formulary is the document that decides your case.

What the prescribing numbers show

Coverage is shrinking. Use is not. Medicaid GLP-1 prescriptions across the class:

Year	Medicaid GLP-1 prescriptions	Change on prior year
2019	1,286,612	—
2020	1,777,025	▲ 38.1%
2021	2,743,573	▲ 54.4%
2022	4,257,252	▲ 55.2%
2023	6,783,761	▲ 59.3%
2024	8,437,618	▲ 24.4%

A 6.6-fold increase in five years. Set that beside a state count falling from sixteen to thirteen and the tension is obvious: demand rose faster than budgets, and some states responded by narrowing the door rather than widening it.

The composition changed as much as the total:

Drug	2019	2024	Change
Ozempic	158,204	3,296,862	▲ 1,984%
Trulicity	452,678	2,104,308	▲ 365%
Wegovy	0	1,092,379	new
Mounjaro	0	944,209	new
Zepbound	0	274,778	new
Rybelsus	103	250,611	▲ 2,433×
Victoza	587,668	313,276	▼ 47%

Rybelsus is shown as a multiple rather than a percentage because 103 prescriptions to 250,611 is a 243,212% rise, which reads as a typographical error rather than a number. Ozempic grew more than twenty-fold. Victoza, the market leader in 2019, roughly halved. Wegovy, Mounjaro and Zepbound went from not existing to nearly 2.3 million prescriptions between them. This is a class that reorganised itself inside five years, and state budgets were writing rules against a moving target.

How to check your own state

Do not rely on any table, including this one, as the final word. Coverage changes in budget cycles and the list above has already moved twice in six months.

• Find your state Medicaid programme's preferred drug list, sometimes called the PDL. It is published, and it is the document that governs.
• If you are in managed care, check your plan's formulary too, not just the state's. They are different documents and the plan's is the one that pays.
• Look for the indication, not the drug. Ozempic covered for diabetes tells you nothing about whether Wegovy is covered for weight management.
• Ask what prior authorisation requires before the appointment, so the documentation can be submitted the first time rather than after a denial.

If your state does not cover it

Thirty-eight states do not, so this is the more common position, and it is less bleak than it was a year ago.

Manufacturer self-pay pricing has fallen sharply. As of August 2026, read from the manufacturers' own pages: Wegovy self-pay starts at $149 a month, and Zepbound runs $299 to $449 depending on dose. That is a different proposition from the roughly $499 these programmes charged for much of their existence, and it is close to compounded pricing while being an FDA-approved product.

The full comparison across every drug and payment route, with each figure dated at source, is in our GLP-1 cost index. If you have no coverage at all, the cheapest GLP-1 without insurance works through the options in order.

One route worth knowing if you have been refused on weight-management grounds: Zepbound gained a second FDA indication in December 2024 for moderate to severe obstructive sleep apnoea. A separate diagnosis is a separate coverage conversation, and it is under-used.

State coverage figures and prescription counts are from KFF's January 2026 analysis of Medicaid coverage of and spending on GLP-1s, taken from the underlying datasets rather than from secondary summaries. Coverage changes on state budget cycles and has moved twice in the last six months; confirm your own state's preferred drug list before relying on any table, including this one. This is general information, not medical or benefits advice.